Sandoz TV Episode 18: Trailer
Find out what to expect from the newest episode of Sandoz TV.
|Global News||Sandoz Around the World||Sandoz in the Media|
Sandoz receives FDA approval for Glatopa™ as the first generic competitor to MS therapy Copaxone® 20mg
Holzkirchen, Germany, April 16, 2015
Sandoz, a Novartis company, today announced the US approval of GlatopaTM, the first generic version of Teva’s Copaxone® (glatiramer acetate injection) 20 mg/ml one-time-daily multiple sclerosis therapy.
Innovative respiratory inhaler Airflusal® Forspiro® receives Alufoil Trophy 2015
April 16, 2015
AirFluSal® Forspiro®, an innovative respiratory inhaler from Sandoz, has won the coveted Alufoil Trophy 2015 in the Product Preservation category.
Sandoz launches authorized generic version of EXFORGE® in the US
Princeton, New Jersey, March 31, 2015
Sandoz today announced the US market introduction of amlodipine and valsartan combination tablets, a generic version of EXFORGE® made by Novartis.
Sandoz receives approvals in Ireland and Sandoz launches innovative respiratory inhaler AirFluSal® Forspiro® in Portugal and Ireland
Holzkirchen, March 11, 2015
Sandoz today announces the launch of AirFluSal® Forspiro®, an innovative inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD), in Portugal and Ireland.
FDA approves first biosimilar Zarxio™ (filgrastim-sndz) from Sandoz
Holzkirchen, March 06, 2015
Sandoz, a Novartis company, announced today that the US Food and Drug Administration (FDA) approved Zarxio™ (filgrastim-sndz) for all indications included in the reference product’s label.